AEON Biopharma Receives Second NYSE American Notice for Listing Non-Compliance

AEON Biopharma has received an additional notice from the NYSE American LLC regarding its continued listing standards. The company disclosed this development on April 3, 2026, stating that the notification pertains to its non-compliance with certain requirements outlined in the exchange’s rules.

According to AEON Biopharma, the notice specifically addresses its failure to meet Section 1003(a)(i) of the NYSE American Company Guide. This section requires listed companies to maintain stockholders’ equity of at least $2 million if they have reported losses from continuing operations and/or net losses in two of their three most recent fiscal years. The company also noted that it had previously received a separate notice related to other listing deficiencies under NYSE American guidelines. AEON Biopharma stated it is reviewing its options and intends to submit a compliance plan within the required timeframe as part of efforts to address these issues.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: April 3, 2026

Author

GOAI